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Abstract: There are two approaches to reducing the burden of sickness and death associated 
with HIV/AIDS: treatment and prevention. With limited resources, should the focus be on 
prevention or treatment? I discuss the range of prevention and treatment alternatives, examine 
their cost effectiveness, and consider various arguments that have been raised against the use of 
cost-effectiveness analysis in setting priorities for health. I conclude that promoting AIDS 
treatment using antiretrovirals in resource-constrained countries comes at a huge cost in terms of 
avoidable deaths that could be prevented through interventions that would substantially lower the 
scale of the epidemic. 
 
David Canning is Professor of Economics and International Health, Harvard School of Public 
Health, Harvard University, Boston, Massachusetts.  
e-mail: dcanning@hsph.harvard.edu
  0 
There are two approaches to reducing the burden of sickness and death associated with 
the human immunodeficiency virus (HIV) that leads to acquired immunodeficiency syndrome 
(AIDS): treatment and prevention. Treatment for HIV/AIDS involving antiretroviral therapy has 
been proven effective, even in resource-poor settings, in delaying the decline in the immune 
system, the onset of opportunistic infections, and death – and in extending the life expectancy of 
those infected by around four years (Ivers, Kendrick, and Doucette, 2005).  Prevention measures 
to limit the transmission of AIDS include mass media campaigns, condom distribution, peer 
education of prostitutes, the prevention of mother-to-child transmission, voluntary counseling 
and testing, and diagnosis and treatment of other sexually transmitted diseases (since the 
symptoms of these diseases can make it easier for the HIV virus to spread). Despite large 
international aid flows for HIV/AIDS, the needs for prevention and treatment in low and middle 
income countries outstrip the resources available (Joint United Nations Program on HIV/AIDS, 
2005). Thus, it becomes necessary to set priorities. The standard policy prescription is that in 
order that to maximize health, with a limited budget, funds should first be allocated to more cost- 
effective interventions, and only then to interventions with lesser cost effectiveness. With limited 
resources, should the focus of efforts to combat HIV/AIDS be on prevention or treatment?   
Antiretroviral treatment is complex and requires regular monitoring of adherence, 
efficacy, and side effects, with consequent changes in treatment regime when needed, requiring 
large inputs from local health services. Consequently, such treatment is expensive. Studies by 
Marseille Hofmann, and Kahn (2002) and Creese, Floyd, Alban and Guinness (2002) make 
highly favorable assumptions about the costs and benefits of highly active antiretroviral therapy, 
and they still conclude that a dollar spent on prevention is around 28 times more effective in 
reducing the burden of disease, as measured by illness and premature death.  Thus, they conclude 
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that the limited resources available to combat HIV/AIDS in low-income countries should be 
targeted toward prevention rather than treatment. These results produced a rapid response at the 
XIV World AIDS Conference, held in Barcelona in 2002 as described by Boelaert, Van Damme,  
Meessen and Van der Stuyft (2002, several acronyms in the original are spelled out here):   
 
At the Barcelona conference, Richard Feachem  (Global Fund to Fights AIDS, 
Tuberculosis and Malaria), Gro Harlem Brundtland (World Health Organization) and 
Jeffrey Sachs voiced their disagreement with the conclusions of the cost-effectiveness 
analysis studies. All took unequivocal positions, stating, e.g. that ‘The Global Fund will 
never hire such economists’, ‘prevention and treatment must go hand in hand’, and ‘it is 
wrong to accept that we have to choose between prevention or care, doing both is easily 
affordable’. All echoed the call of the activists: ‘10 billion dollars for the Global Fund, 
now!’ and got the blessing of the international health establishment.  
 
Among international health agencies, the consensus view is for a rapid expansion of 
treatment programs in developing countries.  The World Health Organization has made the 
treatment of HIV/AIDS using antiretroviral therapies their priority, aiming to have three million 
people in developing and middle income countries in antiretroviral therapy by the end of 2005 
(the “3 by 5” initiative).  While this goal has not been achieved (there were around one million 
people under treatment in June 2005, (World Health Organization, 2005), the Joint United 
Nations Program on HIV/AIDS (UNAIDS, 2005) has a target of expanding treatment to around 
9.8 million by 2010.    Similarly, the United States through the President's Emergency Program 
for AIDS Relief, a five-year $15 billion plan for to combat AIDS, will focus 80 percent of its 
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resources on treatment and care, with 20 percent going to prevention efforts. In addition, the 
World Bank encourages the use of its loans and grants for treatment of HIV/AIDS. 
A strong case can be made for funding both prevention and treatment of HIV/AIDS. 
However, given the limited resources of low income countries and the fairly low levels of 
funding developed countries have made available in practice, choices have to be made about 
priorities.  It is clear that the economists’ method, cost-effectiveness analysis, is not the prime 
consideration in international organizations’ policy making about HIV/AIDS in developing 
countries; indeed, it has been roundly rejected. I argue that this rejection is a mistake. If the goal 
is to maximize health benefits with the limited resources available, then cost effectiveness 
analysis is the right tool. Counterarguments come down either to putting forward goals other 
than maximizing health benefits with HIV/AIDS spending, or to pretending that resources are 
not scarce. 
 I begin with an overview of the effects of the AIDS epidemic in developing countries. I 
then discuss the range of prevention and treatment alternatives, and examine their cost 
effectiveness and the arguments that have been raised against such cost-effectiveness analysis, in 
terms of uncertainties in measurement, particularly when behavioral responses, feedbacks, and 
externalities are present.  A central issue that arises is the ethical basis of cost effectiveness 
analysis in the public policy approach to HIV/AIDS in developing countries.  While other 
criterion can be used for setting priorities, promoting AIDS treatment using antiretrovirals comes 
at a huge cost in terms of avoidable deaths that could be prevented by devoting resources to 
prevention interventions that would substantially lower the scale of the epidemic.  
 
The Health, Economic, and Social burdens of HIV/AIDS 
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HIV/AIDS is a major cause of premature death and imposes a large disease burden 
around the world.  Table 1 shows estimates of the number infected, the adult prevalence rate and 
the deaths from AIDS.  There were about 40 million people in the world in 2005 infected with 
HIV, about 26 million of them in Africa, where the prevalence rate is 7.2 percent among the 
adult population aged 15 to 49.  HIV/AIDS is the major health problem is Africa. A standard 
measure of the health costs and benefits is disability-adjusted life years (DALYs).  About 18 
percent of all disability-adjusted life-years lost due to health problems in Africa during 2002 
were due to HIV/AIDS (World Health Organization, 2004). Most of the burden is due to early 
death. The disability weight (set by a panel of experts)  associated with HIV is 0.135 while AIDS 
has a weight of 0.505, where 0 corresponds to no disability and 1 corresponds to near death  The 
regional figures mask substantial variation, particularly in Africa where a number of countries 
have exceptionally high prevalence rates; Swaziland, Botswana, Lesotho, Zimbabwe, Namibia, 
and South Africa are estimated to have prevalence rates in excess of 20 percent.  Nigeria, the 
most populous county in Africa has a relatively low rate but still has a large number of HIV-
infected people.  
Prevalence rates are usually based on samples of pregnant women at clinics and these 
figures may overstate prevalence rates due to selection bias (Boerma, Ghys and Walker, 2003).  
Population-based surveys consistently find lower estimates of prevalence, leading to speculation 
that actual prevalence rates may be 25-40 percent lower than standard estimates (Halperin and 
Post, 2004).  
In addition to the health impact, HIV/AIDS also has large potential impacts on the 
economy and society. Health can be considered as a form of human capital and health 
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interventions can boost school attendance (Bleakley, 2003; Miguel and Kremer, 2004) and 
worker productivity (for example, Basta et al. 1979; Savedoff and Schultz, 2000; Schultz, 2002).  
Shastry and Weil (2002) carry out a calibration based on microeconomic estimates of the effects 
of health on worker productivity to show that population health should have a substantial effect 
on national income levels, a conclusion that is supported by cross-country growth studies 
(Bhargava et al., 2001;  Bloom, Canning and Sevilla, 2004).  
  Despite this evidence that population health in general may be associated with higher 
income levels, there is little evidence that HIV/AIDS has led to a substantial reduction in income 
per capita (Bloom and Mahal, 1997; Cuddington, 1993). Diseases with high adult morbidity 
(sickness), such as malaria, will reduce the productivity of workers and lower GDP per capita, 
while diseases with high child morbidity, such as malaria and hookworm may reduce school 
attendance. The effect of a disease whose burden is mainly in the form of higher mortality 
(death) is less clear.  The loss of workers will lower output but their deaths will also lower total 
population, reducing both the numerator and the denominator in GDP per capita. Deaths from 
HIV/AIDS are concentrated among young adult women and middle-aged men and there was 
some evidence in the early stages of the epidemic that it was more prevalent among those with 
high socioeconomic status, though current evidence is more mixed (Wojcicki, 2005), and these 
selectivity effects could reduce GDP per capita.
1  
                                                 
1  In a simple economic model, if there is a fixed factor, such as land, then a reduction in the 
population may increase the income per capita of the survivors (Young, 2004). Of course, in a 
more complex economic model with economies of scale and agglomeration, a reduction in 
population can also decrease income per capita of survivors.  
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   While HIV/AIDS does not seem, so far, to have reduced income per capita substantially, 
income per capita is not a welfare measure.  A more comprehensive welfare measure that 
included the suffering and death of its victims would show a large welfare reduction in societies 
with HIV/AIDS (Jamison, Sachs and Wang, 2001; Crafts and Haacker, 2004). In addition to the 
direct welfare effect of lower health, resources devoted to preventing and treating HIV/AIDS 
will reduce consumption of other goods. Estimating the size of this effect requires national AIDS 
accounts that trace the flow of funds spent on prevention and treatment, combining household, 
government and international donor expenditures.  Table 2 reports preliminary results for total 
expenditures on HIV/AIDS from all sources from national AIDS accounts for a number of 
countries that suggest that in relatively low prevalence settings, the financial burdens have so far 
been small. The figures for Kenya indicate that in very high prevalence, low-income, settings 
spending on HIV/AIDS can consume a significant proportion of GDP.   
  While the macroeconomic effects of HIV/AIDS to date have been muted, the long run 
effects are potentially large.  A shorter prospective lifespan may decrease incentives to invest in 
human capital (Kalemli-Ozcan, Ryder and Weil, 2000) and to save for the future (Bloom, 
Canning and Graham, 2003). The deaths of parents and the creation of a generation of AIDS 
orphans may lead to low levels of health and educational investments in these children and low 
productivity in the future (Bell, Devarajan and Gersbach, 2004).  Many African countries have a 
tradition of fostering relatively large numbers of children to relations and some evidence that 
existing AIDS orphans can be absorbed into this system with relatively little hardship in terms on 
nutritional and educational outcomes (Ainsworth and Filmer, 2002), but this system may break 
down under the strain of greater numbers of orphans. 
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  High rates of HIV/AIDS can have major effects on social relationships and institutions, 
although these effects can be difficult to quantify. The high level of stigma associated with 
HIV/AIDS can reduce trust in the community, while high mortality and the strains imposed by 
coping with extreme ill health before death can weaken institutions, such as families, community 
groups, firms, and government agencies. The weakening of these elements of social capital may 
have large long-run economic consequences (Haacker, 2004). 
 
Epidemiology, Prevention and Treatment 
 
  Epidemiology and Transmission 
The HIV virus creates a U-shaped path of infection and infectiousness. In the first few 
months after infection, the HIV virus replicates rapidly and may cause mild flu-like symptoms.  
In this stage the viral load is high, particularly in genital fluids. The emergence of an immune 
response, partly through CD4 cells that target the virus, leads to a rapid decline in the viral load 
to very low, though still detectable, levels.  In this stage, which may last for 10 years or more, the 
disease has few clinical symptoms. The CD4 cells are a target of the virus and are gradually 
eliminated, however, and over time the immune response weakens. At some point (usually when 
the CD4 concentration has fallen from its normal level of around 1000 to below 200 per ml) the 
viral load again rises rapidly and is associated with a rapid decline in the overall immune system. 
At this point the body is open to opportunistic infections (in Africa, tuberculosis is common), 
usually leading to death within two years. People who have HIV are most infectious to others 
when their viral load is high, leading to a U-shaped rate of infectiousness.  Based on a study of 
discordant couples (where one partner has the  HIV virus, but the other does not) in Uganda, the 
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risk of causing a new infection is highest in the first two and a half months after infection (a 
transmission risk of 0.0082/coital act), and in the last twenty four months of life (0.0028/ coital 
act), with a low of 0.0007/ coital act in the middle period (Wawer et al., 2005). While these 
transmission rates per sex act are low, the cumulative probability of transmission from repeated 
unprotected sex with an infected partner quickly becomes large.    
In developing countries, HIV/AIDS is transmitted mainly through heterosexual sex and 
through mother-to-child transmission before or during birth, or through breast feeding. High risk 
groups for heterosexual transmission are commercial sex workers and their clients.  In many 
countries, male long distant truck driver and temporary work migrants provide a vector for 
infection into their local communities. In some countries, despite high infection rates in these 
high-risk groups, prevalence rates among the general population remain low.  If each case in the 
general population infects less than one other person on average, initial infections tend to have a 
very limited impact on the general population.  If, however, each new infection leads to more 
than one subsequent infection on average, then an epidemic occurs in the general population.  
These two different cases have implications for whether a country should focus its prevention 
efforts on the high-risk groups or target the general population.  
An important issue is why HIV prevalence rates are so high in some African countries.  
Halperin and Epstein (2004) argue that while the number of sexual partners reported in Africa is 
similar to that found in other regions, the pattern of sexual activity, with concurrent long term 
relationships being common, as opposed to the serial monogamy found elsewhere may be a 
factor (one-off casual sex and commercial sex are common in many countries).   A study of four 
Africa cities with very different levels of HIV (Auvert et al., 2001), comes to the conclusion that 
the driving force behind the differential rates of HIV prevalence is not differences in sexual 
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practices, such as the number of partners, but the rate of transmission of infection per sexual act, 
with high levels of transmission being associated with the presence of other, untreated, sexually 
transmitted diseases and, for men, being uncircumcised. Oster (2005) uses an epidemiological 
model to argue that the higher transmission rates in Africa can explain the difference between 
HIV prevalence in Africa and the United States, though she attributes a greater role to 
differences in sexual behavior and the timing of the epidemic in explaining differences across 
countries within Africa.      
 
 Prevention Options 
  A number of prevention measures can dramatically lower the transmission of HIV/AIDS. 
One set of measures focuses on reducing the rate of HIV transmission through non-sexual 
pathways, from mothers to children, and through blood transfusions.  A second set of prevention 
measures focus on sexual behavior, promoting changes in sexual activity like abstinence, 
reducing the number of partners, and condom use though mass media campaigns, school-based 
or peer education, condom distribution and voluntary counseling and testing.  A third set of 
prevention measures targets transmission rates per unprotected sex act, through treating other 
sexually transmitted diseases and encouraging male circumcision.     
  Without intervention, 15-30 percent of children born to HIV positive (that is, those who 
have the virus) mothers will be infected either before or during birth and a further 10-20 percent 
will be infected via breast feeding. Mother to child transmission can be dramatically lowered by 
giving HIV positive mothers a single dose of nevirapine to the mother at the onset of labor and a 
single dose to the infant at birth (Hashimoto, Kapiga and Murata, 2002).  This policy may reduce 
transmission to below 3 percent at birth.  The issue of breast feeding is more difficult, because an 
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argument can be made that in situations of high child mortality the benefits to children of breast 
feeding by HIV-positive mothers (without the addition of any foods) for the first six months 
outweigh the risks from possible HIV transmission (Coutsoudis et al., 2002). Breast milk confers 
direct health benefits to children compared to formula milk and additional health problems can 
also arise when there is a lack of clean water to make up the formula milk from powder.  Using 
HIV-infected blood in a transfusion produces almost certain transmission of the disease to the 
recipient, but it is now easy to test blood products before use.  
  Reducing the transmission of the HIV virus that occurs through sexual activity can be 
done either by reducing certain kinds of sexual activity or by making sexual activity less likely to 
transmit disease. Voluntary counseling and testing for HIV is widely available in developing 
countries and has a role in prevention strategies. Rapid tests based on finger prick blood spots or 
mouth swab are cheap and widely. Due to the likely effect of learning one’s HIV status, 
counseling services are required, both before and after testing. Voluntary counseling and testing 
can play a role in prevention by reducing risky sexual behavior in those who are HIV positive, 
particularly if there is joint counseling of couples. 
The effects of mass media national campaigns to influence behavior are difficult to 
estimate since a control group is usually not available.  The ABC -- Abstain, Be Faithful, Use 
Condoms -- initiative in Uganda, combined with a high level of political commitment to HIV 
prevention, was successful in significantly reducing the prevalence of AIDS (Cohen, 2004).  In 
mass efforts such as this, it is difficult to ascribe success to individual components (these is a 
debate about the relative importance of condoms in the ABC strategy) but they do provide 
evidence that broad-based and well supported efforts at behavior change can be effective 
prevention strategies.  The impact of mass media campaigns tends to be short (Vidanapathirana, 
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Abramson, Forbes and Fairley, 2005) and there needs to be an ongoing effort. These mass 
campaigns can be aided by condom distribution, and more targeted HIV education programs 
aimed at youth in and out of school.   
  A number of interventions can reduce transmission rates for unprotected sex. HIV 
transmission is higher when the presence of other sexually transmitted diseases gives rise to open 
sores that allow entry by the virus to the blood stream – such untreated sores are common in sub-
Saharan Africa.  Treatment of these sexually transmitted disease is simple and cheap and can 
prevent the spread of HIV.  While some of these interventions have been successful,  the effect 
of such programs appears to be highly dependent on circumstances (Grosskurth et al., 1995; 
Gilson et al., 1997; Sangani, Rutherford and Wilkinson, 2005)  
Observational evidence suggests that HIV rates are higher among uncircumcised men in 
Africa, and that the countries with highest rates HIV also have the highest proportions of 
uncircumcised men (Caldwell and Caldwell,1996).  The foreskin is rich in white blood cells 
which may act as an entry point for HIV.  Recent evidence from a randomized trial appears to 
support the beneficial effects of male circumcision in reducing HIV transmission (Cohen, 2005).    
 
Treatment  
Highly active antiretroviral therapy for HIV/AIDS patients, while effective in most 
patients, is difficult and requires a high level of medical supervision. Patients should have a CD4 
test (CD4 cells are part of the immune system that help fight infections and low counts indicate a 
reduced immune response) or viral load (the number of HIV viruses found per milliliter of 
blood) to find if therapy is appropriate and at intervals to see if it is proving effective.  World 
  11 
Health Organization guidelines are for antiretroviral therapy to begin when the CD4 count is 
below 200. 
Patients usually visit a clinical once a month to get a new supply of drugs, to discuss their 
symptoms and to take medical tests. The drugs used in treatment are toxic and patients must be 
monitored for side effects as well as efficacy. In addition, effectiveness depends on high levels of 
adherence (at least 85 to 90 percent). Counseling and follow-up to ensure adherence are required, 
especially since many people with HIV/AIDS suffer from depression which may affect 
adherence. Antiretroviral therapy treatments can interact with drugs for other illness, a serious 
problem since often half of those entering treatment with a CD4 count of 200 are very likely to 
have opportunistic infections that require treatment.  
HIV mutates rapidly, and while many mutations are less virulent, resistance to 
antiretrovirals emerges; antiretroviral therapy usually consists of a cocktail of three drugs to 
combat the emergence of resistance. Once resistance to the first line of antiretroviral therapy 
emerges, patients can be treated with second- or third-line drug regimes. Medeiros, Diaz and 
Filho (2002) find in a Brazilian study that the average duration of benefits from first line 
antiretroviral therapy was only 14.1 months.  This finding suggests that a need for second line 
antiretrovirals will quickly emerge in Africa, but while drug costs of first line treatment are now 
low, with generic drugs being available at a cost of around $175 per year, the costs of the second 
line drugs can be ten times higher.  
In addition to antiretrovirals, other measures can be used to prevent and treat 
opportunistic infections.  The major opportunistic infection, and leading cause of death for those 
with AIDS in Africa, is tuberculosis.  All HIV-positive patients, particularly those with latent 
tuberculosis, can take a drug to prevent its emergence. Multivitamin supplements can also reduce 
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the effects of opportunistic infections (Fawzi et al., 2004). Direct treatment of opportunistic 
infections in HIV positive patients can be effective (for example, Grant, Kaplan and Cock, 
2001).  In particular, the standard treatment of tuberculosis (directly observed treatment, short 
course) is highly effective in general and can be equally effective in HIV- positive patients 
(Davies et al.,1999).  HIV-positive patients with tuberculosis can also be given drugs to prevent 
the onset of pneumonia, which can dramatically reduce mortality rates. 
 
The Cost-effectiveness Bottom Line  
Many high and middle income countries provide both prevention and treatment.  Based 
on the high valuations of health found in cross-country estimates of willingness to pay to avoid a 
small chance of death (Aldy and Viscusi, 2003), Jamison and Sachs (2001) argue that countries 
should set the cut-off for cost effective health interventions at around three times GDP per capita. 
This implies that countries with a gross national product per capita in excess of $500 should 
almost certainly be undertaking all of the prevention interventions outlined here, as well as first- 
line  antiretroviral therapy.  For example, Brazil is successfully providing universal access to 
antiretroviral therapy (Teixeira, Vitoria and Barcarlo, 2004). 
The tough issue arises in the least developed countries in which resource constraints are 
so tight that neither sufficient prevention nor treatment are being carried out. Given the resource 
constraints, cost effectiveness analysis is a way of setting priorities. Table 3 sets out the range 
cost effectiveness estimates that have been used in four papers that compare interventions.  The 
figures in columns A, B and C calculate cost effectiveness figures using estimates of health 
benefits and costs found in particular studies, Marseille, Hofmann and Kahn  (2002), Creese, 
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Floyd, Alban and Guinness (2002), and Masaki, Green, Greig, Walsh, and Potts (2003) 
respectively. 
    A problem with cost effectiveness studies for prevention efforts against an opportunistic 
disease is that the overall benefits depend on the epidemiology of the disease.  The effectiveness 
of prevention efforts tend to be higher when incidence rates are high, because  more instances of 
transmission can be prevented.  We also need to estimate not only the number of infections 
directly avoided by the target group, but the extent to which each infection can cause subsequent 
infections in a multiplier process.  Changing the behavior of the population may also have 
feedback effects by changing risk and incentives for individuals. 
A full cost effectiveness analysis therefore has to be embedded in an epidemiological 
model.  Oster (2005) does this to examine the effect of treating sexually transmitted diseases on 
the course of the epidemic.  This approach requires modeling different sub-populations; for 
example, single men and women, married men and women, and commercial sex workers and 
their clients are often modeled as distinct subgroups, but others groups may also be modeled 
depending of their importance in a particular setting, like intravenous drug users and urban 
versus rural dwellers.  The model needs to include rates of sexual interaction and other types of 
transmission within and between groups, and calibrate the rate of transmission rates of HIV in 
different sexual activities.   
Epidemiological models usually find multiplier effects, so that individual actions that 
reduce personal risk also reduce subsequent risk to others. However the interactions in such 
models are complex and may even reverse the direct effects of a prevention intervention.  For 
example, Kremer and Morcom (1998) show that if HIV-negative people abstain from sexual 
activity, this can increase the proportion of HIV- positive individuals among the sexually active, 
  14 
thus increasing the chances of infection for others who remain sexually active.  This negative 
externality particularly affects those who are highly sexually active who are more likely to get, 
and then to spread, the disease.  Abstinence by those who would otherwise have a small number 
of partners can have the apparently paradoxical effect of increasing prevalence rates, despite 
reducing overall sexual activity. 
The final two columns of Table 3 give cost effectiveness estimates based on Hogan, 
Baltussen, Hayashi, Lauer, and Salomon (2006). The effects of each intervention are embedded 
in a common epidemiological model.  This allows for interactions between interventions, and the 
possibility of complex feedback effects. The first column gives the cost effectiveness of each 
intervention on its own (if no other interventions were used) while the second gives the 
incremental cost effectiveness of each intervention based on the optimal sequencing of 
interventions, introduced as ranked by their cost effectiveness.    
The interventions in Table 3 are ordered roughly in order of cost effectiveness.  This 
ranking suggests that mass media messages are highly cost effective at changing behavior and 
reducing the transmission of HIV.  Peer education, condom distribution, and treatment of 
sexually transmitted diseases for commercial sex workers are also highly cost effective.  The 
treatment of tuberculosis is highly cost effective in those who are HIV positive as well as the 
general population.  These interventions costs between $1 and $20 per DALY gained. 
Blood transfusion safety and the prevention of mother to child transmission through 
single dose nevirapine are next in the ranking both with costs less than $50 per DALY gained.  
Then comes the diagnosis and treatment of sexually transmitted diseases, voluntary counseling 
and testing, and condom distribution to medium and high risk women, which probably have costs 
less than $100 per DALY gained and are always estimated at less than $300 per DALY. 
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Similarly preventive therapy against tuberculosis for those who are HIV-positive costs less than 
$300 per DALY gained.   Prevention of mother to child transmission through using formula milk 
rather than breast feeding has a wide range of estimated costs and is dependent on the trade off 
between avoiding HIV infection and the extra risks to the child that come from using formula 
milk rather than breast feeding. School-based HIV/AIDS education has low cost effectiveness 
due to the relatively small effects on behavior it seems to bring about.    
The least cost effective interventions are treatment using antiretroviral therapy.   The 
studies reported in columns A, B and C have found that first line antiretroviral therapy has a cost 
in excess of $1,000 per DALY loss averted (the figure of $350 in the first column reflects only 
drug costs at the time and not the cost to the health system of providing antiretroviral therapy). 
The downward trend in drug prices means the figure today is probably somewhat smaller, 
perhaps between $500 and $600 as reported in the most recent study shown in Table 3.   
Second-line drugs remain expensive in low income countries making this the least cost 
effective intervention we consider (the figure $1977 in the fourth column is the average cost 
effectiveness of a policy of providing both first  and second line antiretroviral therapy - second 
line could never be provided on its own - while the figure $5175 in the fifth column is the 
marginal cost effectiveness of moving to second  line after using first-line antiretrovirals).  
Table 4 shows the results the costs and loss of disability-adjusted life-years averted for 
three different policies in 20 high mortality countries of Africa. The first policy is using all the 
prevention interventions with cost effectiveness calculated in the final column of table 3, with 
the exception of school-based HIV/AIDS education.  These highly cost effective prevention 
interventions would avoid the loss of  30.9 million disability-adjusted life-years at a cost of $859 
per year. The alternative policy of providing first line antiretroviral therapy would avoid the loss 
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of 2.4 million disability-adjusted life-years at a cost of $1350 million.  Providing both first and 
second line antiretroviral therapy would raise the health gains only marginally, but at a large 
additional cost. 
  Focusing on prevention before turning to antiretroviral therapy will bring large health 
gains mainly in the form of infections avoided. Table 4 shows that a focus on prevention in the 
high mortality countries of Africa will reduce new HIV infections in the region by around 3.53 
million per year, as compared with an estimated reduction of 40,000 a year with antiretroviral 
therapy.  If the need for both treatment and prevention could be met, or if there were no 
resources available at all, priority setting would not be required.  UNAIDS (2005) estimates that 
$8.9 billion will be available for spending on HIV/AIDs in low and middle income countries in 
2005. Because this amount is insufficient to meet all needs, redirecting this flow towards 
prevention could have significant effects. 
There is natural uneasiness about having to make such a “tragic choice” between 
prevention and treatment (Calabresi and Bobbit, 1978).  Such tragic choices are inevitable in low 
income countries where resources are so tightly constrained, highlighting the need for policies to 
support economic growth and poverty reduction to make such choices less necessary in the 
future. 
 
Is Cost-Effectiveness Analysis Trustworthy for Priority Setting? 
 
A number of arguments have been put forward for an emphasis on highly active 
antiretroviral therapy over prevention, even in the face of the evidence which suggests it is less 
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cost effective than prevention (for example, Boelaert et al., 2002; Farmer, 2003;  Mukherjee et 
al., 2003). We consider the arguments in turn.  
 
The Number Infected with AIDS is So High  
One argument is that the scale of the HIV/AIDS epidemic is so great, and so threatening 
to overall social and economic development, that it constitutes an emergency that requires a 
direct response (Stabinski et al., 2003). HIV/AIDS is the biggest single health problem in Africa, 
accounting for 12 percent of the disability-adjusted years of life lost, followed by malaria, 
respiratory infections, and injuries (11, 10 and  9  percent of total disability-adjusted years of life 
lost, respectively (World Health Organization, 2004). Thus, it may seem obvious that health care 
priorities should be set according to the size of the burden imposed by the disease, and 
HIV/AIDS has  the largest burden.   
Using the burden of disease as a priority setting tool, however, makes an elementary 
mistake. Spending money focused on the largest health problem, or in proportion to the size of 
the problem, equalizes spending across needs, but does not maximize health produced.  For 
example, if nothing could be done to reduce the burden of HIV/AIDS, then spending anything on 
it at all would be foolish.  Maximizing health outcomes requires that at the margin the cost 
effectiveness of interventions be equalized.  We should use the most cost-effective health 
interventions until they are exhausted (no more cases left to prevent or treat) or cost effectiveness 
falls due to diminishing returns, for example due to the difficulty in identifying rare cases, and 
then move on to the next most cost effective intervention. This logic argues that there is no need 
to know the total burden of each disease for priority setting, only the marginal cost-effectiveness 
of interventions (Williams, 1999)..  
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One argument against this marginal view of priority setting is that certain health care 
policies may have fixed costs (Murray and Lopez, 2000).  For example, most of the costs of 
research and development are fixed. In the simplest possible case, where research leads to a 
breakthrough cure with no marginal cost per patient, the expected cost effectiveness of research 
is simply the cost of the research times the probability of success, divided by total burden of the 
disease in disability-adjusted life-years (on the grounds that this burden can then be avoided if 
the research is successful).  Development of an effective HIV/AIDS vaccine would bring 
enormous benefits because of the many millions of HIV infections that could be avoided, which 
justifies large investments even if the probability of success is low.  
 There may also be fixed costs in the implementation of interventions.  If only a small 
number of interventions are feasible due to institutional constraints, it may be better to focus on a 
few reasonably cost-effective interventions for high burden diseases that will produce a large 
total health gain rather than implement a similar number of highly cost effective but small-scale 
interventions. 
In the case of HIV treatment and prevention, however, it is difficult to argue that a focus 
on antiretroviral treatment, while being less cost effective, will produce a greater total health gain 
than a focus on prevention. For example, Ainsworth and Teokul (2000) accept the idea that there 
are administrative as well as financial constraints and that we should focus on limited number of 
interventions, but they still argue for priority to be given to changing the behavior of the groups 
most at risk, treating opportunistic infections in those with HIV, and preventing the potential 
economic and social consequences of AIDS, for example through programs to ensure the welfare 
of orphans. 
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Nothing in the consideration of the effects of the scale of the HIV/AIDS epidemic would 
lead a policy-maker to put greater emphasis on treatment rather than prevention. Indeed, the 
enormous scale of the epidemic and its social and economic consequences suggests the 
importance of spending available resources as effectively as possible. Prevention efforts will 
tend to reduce the scale of the disease while treatment focuses on its symptoms.  As shown by 
Table 4, promoting treatment before widespread prevention efforts denies the very interventions 
that can reduce the scale of the disease.   
 
Cost-effectiveness Analysis Overstates Returns to Prevention and Understates Returns to 
Treatment  
The idea of a disability-adjusted life year, though commonly used in cost effectiveness 
studies, may be called into question as a measure of health (for example, Anand and  
Hanson,1997) .  The disability-adjusted life-year puts different weight on different disability 
states, and weights a year of life at different ages differently, based on the recommendations of 
expert committees, and discounts future disability-adjusted life  years at a rate of 3 percent a 
year. All of these methods raise questions.  Cost-effectiveness analysis also requires a number of 
judgment calls by the researcher, such as how to allocate overhead costs among several 
activities.  However, most of the burden of HIV/AIDS is in the form of premature death, making 
it relatively insensitive to how disability is weighted.  The other factors seem unlikely to produce 
a bias in favor of prevention.  
With regard to the reliability of cost-effectiveness estimates of prevention efforts, the 
results on the cost effectiveness of mother to child transmission through single dose nevirapine 
are high and fairly uniform across a range of studies.  The effectiveness of treatment of sexually 
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transmitted diseases, on the other hand, seems to be dependent on context (Sangani, Rutherford 
and Wilkinson, 2004). For interventions such as information, education, and counseling, short-
run behavior change can be observed, but studies do not usually provide convincing evidence of 
effects on long-run behavior or disease incidence (Grassly, 2001; Walker, 2003). Instead, long-
run estimates are usually constructed through an epidemiological model that estimates the effect 
of the behavior change on prevalence rates.  
 The case for prevention through behavior change largely rests on the experience of 
Uganda (the ABC mass media campaign) and Thailand (where efforts concentrated on 
commercial sex workers), where a high level of political commitment, and multiple channels of 
communication, translated into successful efforts to reduce the spread of HIV/AIDS.  There is 
the question of how replicable these success stories are in other countries.   
Overall, the evidence for the cost effectiveness of prevention is clear-cut for the non-
sexual pathways, mother to child transmission and blood transfusion safety.  The effects of 
interventions that change behavior, or change transmission rates, need to be calculated in an 
epidemiological model that calculates how incidence and prevalence rates respond to the change. 
An epidemiological model can always be questions, because it is typically built on many 
parameters, but such models can still generate reliable results.  
The cost effectiveness of treatment could also change if full account is taken of 
measurement problems and externalities.   One important issue is that the effectiveness of 
antiretroviral therapy is highly dependent on keeping individual adherence to the therapy 
regimen above 85 percent, since below this level of adherence, the efficacy of the treatment falls 
off quickly.  While adherence levels have been high in small-scale research studies in Africa, 
  21 
there is a real concern that rapid expansion of treatment provision will lead to lower levels of 
counseling and support, and a fall-off in adherence (Gill et al., 2005).   
    The case for prevention is based, to a large extent, on the externality that each infection 
leads to added transmission to others, so that the public benefits of prevention efforts outweigh 
the private benefits.  Treatment may also have externalities that are not included in cost benefit 
analysis. One such benefit is that making HIV/AIDS a treatable illness may reduce the stigma 
associated with it (Castro and Farmer, 2005), though evidence on this is so far meager.  Another 
possible externality is that when treatment reduces the viral loads in those who have HIV/AIDS, 
it also can reduce the possibility of infecting sex partners -- though this effect is counterbalanced 
by some extent the longer lifespan and additional sexual activity for transmission of those in 
treatment.   
Possible externalities on behavior may also arise.  Since the availability of treatment 
raises the possibility that testing may lead to treatment, testing for HIV may become more 
common, allowing people who learn that they are HIV-positive to change their sexual behavior. 
However, the current World Health Organization recommended treatment regime in low income 
countries is to begin antiretroviral therapy at a CD4 count of 200, at which time opportunistic 
infections are likely to be present. Under this standard, early testing for HIV is unlikely to lead to 
earlier treatment than waiting for AIDS to manifest through opportunistic infections, and then 
seeking testing and treatment.    
A major possible negative externality is that because the availability of treatment lowers 
the cost of being infected, people may become more risk taking.  There is evidence of such an 
effect in the United States (Goldman, Lakdawalla and Sood, 2004) as well as evidence of 
widespread reductions in condom use in Kenya in response to (incorrect) announcements of 
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cures for AIDS being found (Over et al., 2004).  Treatment may also have another negative 
externality, in the form of the development and transmission of drug resistant strains of HIV, 
though existing evidence on this suggests that it may not be a major concern in Africa in the 
foreseeable future (Blower et al., 2005).  
  Other externalities from HIV/AIDS are caused by the reduction in care to other members 
of the family when an AIDS victim dies.  The death of a father or mother may reduce family 
income or the provision of child care, and may have enormous repercussions on children's 
development. But these externalities also apply to HIV/AIDs cases avoided through prevention 
methods and so are unlikely to tip the balance. 
An important possible negative externality of a focus on treatment is that it absorbs 
scarce health sector workers from other activities, including cost effective treatments of other 
diseases.  In the long run the supply of doctors and nurses can respond to the additional demand, 
but in the short run the high level of funding for AIDS treatment may reduce health sector 
workers available for other activities (Over, 2005).   The shortage of even basic medical facilities 
and personnel in the poorest countries of Africa, particularly in the rural areas, make it difficult 
to see how antiretroviral treatment can be rolled out to provide close to universal coverage in the 
next few years. Many low income countries have difficulty providing very simple, and highly 
cost effective, medical services such as vaccinations for children, which makes it seem 
implausible that they can provide a national network of AIDS treatment facilities.       
   Another possible externality to treatment interventions is that "learning by doing" can 
increase future cost effectiveness.  Even modest gains in cost effectiveness would increase the 
number of countries for whom antiretroviral therapy would become an affordable intervention.  
For example, Farmer et al. (2001) experiment with basing initiation of antiretroviral therapy on 
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the failure of conventional treatments for opportunistic infections, rather than laboratory tests 
such as CD4 counts.  Badri et al. (2004) suggest that while using symptoms as a guide to 
initiating antiretroviral therapy reduces the number of eligible patients, relative to using a CD4 
count, it does not affect mortality rates.  However, most current treatment programs explicitly 
exclude research as a goal.  
  Evidence on these positive and negative externalities is not conclusive and more research 
into their magnitudes is required. My reading of the existing evidence is that the risk of negative 
externalities of treatment – that is, widespread treatment leading to higher infection rates – is at 
least as high as the possibility of positive externalities from treatment. Thus, using positive 
externalities as an argument for a large-scale treatment would require new evidence of a large net 
positive spillover effect. Until then, given the very large gap between the cost-effectiveness 
estimates for prevention and treatment, it is not likely that correcting measurement errors will 
reverse the ranking. 
 
Ethical Arguments    
  Three common ethical arguments are put forward for emphasizing antiretroviral 
treatment: the need to save those whose lives are immediately at risk, the presence of a common 
bond with AIDS patients, and the need treat people equally globally, and.
 2    
One common argument in favor of highly active antiretroviral therapy in developing 
countries is the “rule of rescue" (Jonson, 1986), which argues that people feel a psychological 
imperative to save those whose lives they see to be in immediate danger, irrespective of 
opportunity cost. While the rule of rescue has undoubtedly been a strong force in making 
                                                 
2 There are also a number of arguments that could be summarized under the heading of "political economy", such as 
that treating some people will raise political pressure for further treatment and prevention.  This issues are not dealth 
with here but seem unlikely to have effects large enough to lead to a support of treatment over prevention. 
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antiretroviral therapy a priority (Feachem, 2002), it raises difficult issues. McKie and Richardson 
(2003) examine the conflict between the rule of rescue and cost-effectiveness analysis.  In the 
cost-effectiveness analysis of treatment and prevention of HIV/AIDS, those who are ill with full-
blown AIDS do not receive a higher weight than those who could be prevented from getting an 
HIV infection in the first place (though the later gains are discounted by time).  In contrast, the 
rule of rescue gives absolute priority to currently identifiable victims at the expense of a larger 
number of potential victims who have not yet been identified. It is difficult to argue that being 
identifiable gives extra moral weight to a person's claim on resources. 
The rule of rescue implies a commitment to treat a future AIDS case, even if we do not 
wish to support efforts to prevent that same person becoming infected today, when prevention is 
a much cheaper way overcoming the problem and when the person would prefer not to be 
infected, which seems bizarre.   The rule of rescue also suggests that antiretroviral therapy would 
still need to be compared in cost-effectiveness to other treatments for life-threatening conditions. 
There are many highly cost effective life-saving interventions in developing countries -- for 
example treatment of tuberculosis, and basic vaccinations for children -- which cost around $20 
per loss of disability-adjusted life year averted. 
  One reason for an emphasis on treatment is that there exists a global community of 
people concerned about HIV/AIDS, and people in this community feel a common bond with 
those with HIV/AIDS, wherever they may be. I once spoke for more cost-effective use of 
resources at a conference and a more politically knowledgeable participant whispered to me 
afterwards that if we did not use the funds for AIDS treatment, there would be no funds at all.  
While it might be more efficient in social welfare terms to concentrate resources on prevention, 
the group whose welfare we are considering may be defined as those with HIV, so that the 
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feeling of community and obligation only occurs after infection.  Funding for HIV/AIDS 
treatment could be viewed as a form of charitable giving (similar, say, to giving by alumni to 
their college or university).  Such charitable giving is always subject to the critique that the funds 
might have been spent with greater effect elsewhere, but such giving is still a desirable form of 
redistribution, raising the welfare of both recipient and giver.  
Both the rule of rescue and common bond arguments essential deny that our goal should 
be maximizing overall population health, instead the focus should be on a particular group. 
While private charity may focus disproportionately on some groups, there is a strong ethical 
counterargument the public policy should give more equal weights to people, as is done in cost 
benefit analysis.   
   A third ethical argument is that the same standard of health care should apply around the 
world. Since antiretroviral therapy is generally available in high-income countries, this argument 
holds that it would be unethical to deny such treatment to those in low-income countries. It could 
be argued that taking ethical claims to our national borders, and then stopping, shows a lack of 
moral stamina. However, ethics frequently draws some distinctions between the imperatives that 
apply to smaller communities with stronger ties, such as within the nuclear family or a nation-
state, and imperatives that relate to fairness and sharing with weaker ties, as in the global 
community.  Even weak ties provide a strong ethical argument that the international community 
should help provide basic goods, such as health care, that are essential elements of creating 
capabilities in developing countries. But this does not suggest complete equality across countries, 
and they do not imply a priority to AIDS treatment over prevention.  
One way of interpreting the argument that the standard of health care should be the same 
around the world is that we should not prioritize between treatment and prevention interventions, 
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instead the international community should make sufficient funds available to do both. But the 
argument that there should not be a resource constraint comes up against the hard reality that 
there is a resource constraint in low-income countries, and antiretroviral treatment does have a 




Developed, middle-income, and even many low-income countries around the world can 
finance both prevention efforts and antiretroviral treatment for HIV/AIDS, but countries with 
very low incomes face binding resource limitations. In these countries, the issue is to what extent 
the international community should fund antiretroviral therapy. Private charity can of course 
choose to focus disproportionate attention on any particular group to which it feels a strong 
connection. However, if the goal is to maximize the health benefits produced, developing 
country governments and international institutions should focus their health spending first on the 
prevention of HIV transmission, before moving on to treatment. The opportunity cost of 
emphasizing HIV/AIDS treatment over prevention in a resource-constrained environment is  
measured in millions of lives needlessly lost.  
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Table 1 
HIV and AIDS Estimates 2005 








25,800,000 7.2  2,400,000 
Swaziland   220,000  38.8  17,000 
Botswana   350,000  37.3  33,000 
Lesotho   320,000  28.9  29,000 
Zimbabwe 1,800,000  24.6  170,000 
South Africa   5,300,000  21.5  370,000 
Namibia 210,000  21.3  16,000 
National 
data for end 
2003. 
Nigeria   3,600,000  5.4  310,000 
Caribbean 
 
300,000 1.6  24,000 
East Europe and Central 
Asia 
1,600,000 0.9  62,000 
South and South East Asia 
 
7,400,000 0.7  480,000 




1,800,000 0.6  66,000 
Oceania 
 
74,000 0.5  3,600 
Western and Central Europe 
 
720,000 0.3  12,000 
North Africa and Middle 
East 
510,000 0.2  58,000 
East Asia 
 
870,000 0.1  41,000 
     
World Total  40,300,000  1.1  3,100,000 
Source: Joint United Nations Program on HIV/AIDS (2005) for regional data. National data are 
for end 2003 are from the UNAIDS/ World Health Organization Global HIV/AIDS 
Online Database, http://www.who.int/globalatlas/default.asp  
a The adult prevalence rate is the proportion of those 15 to 49 years of age living with HIV. 






prevalence rate % 
HIVAIDS 
spending, per 
capita, $US  
As Percentage of 
GDP 
Kenya 2002  15.0  7.61 2.23 
Burkino Faso  2003  6.5  2.04  0.79 
Ghana 2003 3.0 1.33 0.47 
Guyana 2002 2.7  2.71 0.28 
Belize 2003 2.0 6.93 0.19 
Honduras 2001  1.6  3.97  0.43 
Panama 2003 1.5  4.46  0.11 
Thailand 2003  1.3  1.10  0.04 
El Salvador  2003  1.0  5.04  0.23 
Guatemala 2000  1.0  1.18  0.07 
Argentina 2002  1.0  4.53  0.07 
Brazil 2000 0.7 3.61 0.10 
Costa Rica  2002  0.6  2.44  0.47 
Venezuela 2002  0.5  3.05  0.07 
Columbia 2002  0.4  1.01  0.05 
Uruguay 2002  0.3  3.54  0.07 
Mexico 2002 0.3  2.26 0.04 
Chile 2002  0.3 1.39  0.03 
Nicaragua 2002  0.2  1.61  0.21 
Bolivia 2002 0.1  0.45 0.04 
Authors Calculations. Source for HIV/AIDS prevalence rates, expenditures and population, Joint 
United Nations Program on HIV/AIDS (2004).  GDP per capita from World Bank (2005).
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Table 3 
Cost Effectiveness of Prevention and Treatment of HIV/AIDS in Africa 
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   1977  5175 
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Note: Costs are in U.S. dollars for different years.  Also, costs and effectiveness both depend on 
assumptions on the rate of discount to be applied to future costs and the stream of future 
disability-adjusted life-years gained. I have not tried to rebase to a common year to allow for 
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Table 4 
The Cost and Benefits of Prevention and Treatment 













859  30.9  3.53 
Antiretroviral therapy  
first line drugs only 
 
1,350 2.4  0.04 
Antiretroviral therapy  
first and second line 
drugs 
 
6,434 3.2  0.04 
 
Source: Adapted from data in Hogan, Baltussen, Hayashi, Lauer, and Salomon (2006). 
The effect of each treatment and prevention strategy is relative to no intervention. 
 
Note: These are 20 African countries with high child and very high adult mortality rates defined 
by the World Health Organization (2003). It includes all of the countries in Africa with HIV 
prevalence rates over 20 percent. 
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